Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunjan L Shah

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Blood Advances|April 3, 2025
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphomaNiloufer Khan, Parastoo B Dahi, Farhad Khimani, et al.
Blood Cancer Discovery|November 15, 2021
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesDavid J Chung, Gunjan L Shah, Sean M Devlin, et al.
Blood Cancer Journal|April 14, 2025
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphomaAlejandro Luna, Sean M Devlin, Kai Rejeski, et al.
Blood Advances|August 15, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaXavier Deschênes-Simard, Maria Bromberg, Sean M Devlin, et al.
British Journal of Haematology|May 12, 2024
Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profileRoni Shouval, Adam Goldman, Jessica R Flynn, et al.
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Blood Advances|August 25, 2021
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cellsMartina Pennisi, Miriam Sanchez-Escamilla, Jessica R Flynn, et al.
Blood Advances|February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMMKylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Haematologica|June 20, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphomaOhad Benjamini, Shalev Fried, Roni Shouval, et al.
The Journal of Clinical Investigation|September 8, 2020
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantationGunjan L Shah, Susan DeWolf, Yeon Joo Lee, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Blood Advances|April 3, 2025
Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphomaNiloufer Khan, Parastoo B Dahi, Farhad Khimani, et al.
Blood Cancer Discovery|November 15, 2021
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesDavid J Chung, Gunjan L Shah, Sean M Devlin, et al.
Blood Cancer Journal|April 14, 2025
CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphomaAlejandro Luna, Sean M Devlin, Kai Rejeski, et al.
Blood Advances|August 15, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaXavier Deschênes-Simard, Maria Bromberg, Sean M Devlin, et al.
British Journal of Haematology|May 12, 2024
Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profileRoni Shouval, Adam Goldman, Jessica R Flynn, et al.
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Blood Advances|August 25, 2021
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cellsMartina Pennisi, Miriam Sanchez-Escamilla, Jessica R Flynn, et al.
Blood Advances|February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMMKylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Haematologica|June 20, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphomaOhad Benjamini, Shalev Fried, Roni Shouval, et al.
The Journal of Clinical Investigation|September 8, 2020
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantationGunjan L Shah, Susan DeWolf, Yeon Joo Lee, et al.
Pageof 13